AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation to import Durvalumab for sale and distribution. The drug, combined with chemotherapy, treats resectable non-small cell lung cancer without specific genetic mutations. Lung cancer remains a significant cause of mortality in India, highlighting the importance of this development.
Related Posts
Tata Steel’s TV Narendran elected chairman of worldsteel; becomes second Indian to head global body
Thachat Viswanath Narendran, CEO of Tata Steel, has been elected as chairman of the World Steel Association, making him the second Indian in this role […]
Investors lose over Rs 25 lakh crore as Dalal street remains red for 8th consecutive day
- staff
- February 14, 2025
- 0
Investor wealth experienced a significant decline, losing Rs 25.31 lakh crore in eight trading sessions. The BSE Sensex tumbled more than 3%, heavily impacted by […]
No respite! Adani Group stocks plunge up to 11% as Kenya cancels deals after US charges against Gautam Adani
Adani Group stocks continued to fall for a second day, with Adani Enterprises and Adani Ports experiencing significant drops. This comes amidst accusations of bribery […]